InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,104.51
(
1.11%
)
US TECH 100
17,184.20
(
1.21%
)
Dow Jones
38,276.45
(
0.50%
)
Brent Oil
88.40
(
0.28%
)
Bitcoin
64,734.29
(
0.39%
)
Post# of 251609
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: None

Monday, 11/18/2013 10:17:17 AM

Monday, November 18, 2013 10:17:17 AM

Post# of 251609

Glaxo, Theravance get EU marketing approval for Relvar
As expected, GlaxoSmithKline (GSK +0.2%) and Theravance's (THRX -0.6%) Relvar Ellipta gets European marketing approval for COPD and asthma.The news triggers a $15M milestone payment to GSK from THRX. Another $15M will come due upon launch.
The CHMP issued a positive opinion on the drug in September
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up